Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in primary mitochondrial disease with nuclear DNA mutations
NCT05162768Phase 3Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in primary mitochondrial myopathy (PMM) comparing Elamipretide with Placebo (2 arms). Primary endpoint: Six-Minute Walk Test at 52 weeks. Started Apr 2022; status: completed.
02
Drugs
elamipretide
03
Conditions
primary mitochondrial myopathy (PMM)
Beyond the preview
Go deeper on NCT05162768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162768.